Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2

Delphine Antoine; Moein Mohammadi; Madison Vitt; Julia Marie Dickie; Sharmin Sultana Jyoti; Maura A. Tilbury; Patrick A. Johnson; Karen E. Wawrousek; J. Gerard Wall

doi:10.1021/acssensors.1c02664

Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2

Delphine Antoine, Moein Mohammadi, Madison Vitt, Julia Marie Dickie, Sharmin Sultana Jyoti, Maura A. Tilbury, Patrick A. Johnson, Karen E. Wawrousek, J. Gerard Wall

Infectious Disease

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

52 Citations (Scopus)

Abstract

Rapid, sensitive, on-site identification of SARS-CoV-2 infections is an important tool in the control and management of COVID-19. We have developed a surface-enhanced Raman scattering (SERS) immunoassay for highly sensitive detection of SARS-CoV-2. Single-chain Fv (scFv) recombinant antibody fragments that bind the SARS-CoV-2 spike protein were isolated by biopanning a human scFv library. ScFvs were conjugated to magnetic nanoparticles and SERS nanotags, followed by immunocomplex formation and detection of the SARS-CoV-2 spike protein with a limit of detection of 257 fg/mL in 30 min in viral transport medium. The assay also detected B.1.1.7 ("alpha"), B.1.351 ("beta"), and B.1.617.2 ("delta") spike proteins, while no cross-reactivity was observed with the common human coronavirus HKU1 spike protein. Inactivated whole SARS-CoV-2 virus was detected at 4.1 × 10⁴genomes/mL, which was 10-100-fold lower than virus loads typical of infectious individuals. The assay exhibited higher sensitivity for SARS-CoV-2 than commercial lateral flow assays, was compatible with viral transport media and saliva, enabled rapid pivoting to detect new virus variants, and facilitated highly sensitive, point-of-care diagnosis of COVID-19 in clinical and public health settings.

Original language	English
Pages (from-to)	866-873
Number of pages	8
Journal	ACS Sensors
Volume	7
Issue number	3
DOIs	https://doi.org/10.1021/acssensors.1c02664
Publication status	Published - 25 Mar 2022

Keywords

COVID-19
diagnostic
point-of-care
Raman spectroscopy
SARS-CoV-2
scFv antibody fragment
SERS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acssensors.1c02664

Cite this

@article{32deebedd62643c2945be35dd561765a,

title = "Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2",

abstract = "Rapid, sensitive, on-site identification of SARS-CoV-2 infections is an important tool in the control and management of COVID-19. We have developed a surface-enhanced Raman scattering (SERS) immunoassay for highly sensitive detection of SARS-CoV-2. Single-chain Fv (scFv) recombinant antibody fragments that bind the SARS-CoV-2 spike protein were isolated by biopanning a human scFv library. ScFvs were conjugated to magnetic nanoparticles and SERS nanotags, followed by immunocomplex formation and detection of the SARS-CoV-2 spike protein with a limit of detection of 257 fg/mL in 30 min in viral transport medium. The assay also detected B.1.1.7 ({"}alpha{"}), B.1.351 ({"}beta{"}), and B.1.617.2 ({"}delta{"}) spike proteins, while no cross-reactivity was observed with the common human coronavirus HKU1 spike protein. Inactivated whole SARS-CoV-2 virus was detected at 4.1 × 104genomes/mL, which was 10-100-fold lower than virus loads typical of infectious individuals. The assay exhibited higher sensitivity for SARS-CoV-2 than commercial lateral flow assays, was compatible with viral transport media and saliva, enabled rapid pivoting to detect new virus variants, and facilitated highly sensitive, point-of-care diagnosis of COVID-19 in clinical and public health settings.",

keywords = "COVID-19, diagnostic, point-of-care, Raman spectroscopy, SARS-CoV-2, scFv antibody fragment, SERS",

author = "Delphine Antoine and Moein Mohammadi and Madison Vitt and Dickie, {Julia Marie} and Jyoti, {Sharmin Sultana} and Tilbury, {Maura A.} and Johnson, {Patrick A.} and Wawrousek, {Karen E.} and Wall, {J. Gerard}",

year = "2022",

month = mar,

day = "25",

doi = "10.1021/acssensors.1c02664",

language = "English",

volume = "7",

pages = "866--873",

journal = "ACS Sensors",

issn = "2379-3694",

number = "3",

}

TY - JOUR

T1 - Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2

AU - Antoine, Delphine

AU - Mohammadi, Moein

AU - Vitt, Madison

AU - Dickie, Julia Marie

AU - Jyoti, Sharmin Sultana

AU - Tilbury, Maura A.

AU - Johnson, Patrick A.

AU - Wawrousek, Karen E.

AU - Wall, J. Gerard

PY - 2022/3/25

Y1 - 2022/3/25

N2 - Rapid, sensitive, on-site identification of SARS-CoV-2 infections is an important tool in the control and management of COVID-19. We have developed a surface-enhanced Raman scattering (SERS) immunoassay for highly sensitive detection of SARS-CoV-2. Single-chain Fv (scFv) recombinant antibody fragments that bind the SARS-CoV-2 spike protein were isolated by biopanning a human scFv library. ScFvs were conjugated to magnetic nanoparticles and SERS nanotags, followed by immunocomplex formation and detection of the SARS-CoV-2 spike protein with a limit of detection of 257 fg/mL in 30 min in viral transport medium. The assay also detected B.1.1.7 ("alpha"), B.1.351 ("beta"), and B.1.617.2 ("delta") spike proteins, while no cross-reactivity was observed with the common human coronavirus HKU1 spike protein. Inactivated whole SARS-CoV-2 virus was detected at 4.1 × 104genomes/mL, which was 10-100-fold lower than virus loads typical of infectious individuals. The assay exhibited higher sensitivity for SARS-CoV-2 than commercial lateral flow assays, was compatible with viral transport media and saliva, enabled rapid pivoting to detect new virus variants, and facilitated highly sensitive, point-of-care diagnosis of COVID-19 in clinical and public health settings.

AB - Rapid, sensitive, on-site identification of SARS-CoV-2 infections is an important tool in the control and management of COVID-19. We have developed a surface-enhanced Raman scattering (SERS) immunoassay for highly sensitive detection of SARS-CoV-2. Single-chain Fv (scFv) recombinant antibody fragments that bind the SARS-CoV-2 spike protein were isolated by biopanning a human scFv library. ScFvs were conjugated to magnetic nanoparticles and SERS nanotags, followed by immunocomplex formation and detection of the SARS-CoV-2 spike protein with a limit of detection of 257 fg/mL in 30 min in viral transport medium. The assay also detected B.1.1.7 ("alpha"), B.1.351 ("beta"), and B.1.617.2 ("delta") spike proteins, while no cross-reactivity was observed with the common human coronavirus HKU1 spike protein. Inactivated whole SARS-CoV-2 virus was detected at 4.1 × 104genomes/mL, which was 10-100-fold lower than virus loads typical of infectious individuals. The assay exhibited higher sensitivity for SARS-CoV-2 than commercial lateral flow assays, was compatible with viral transport media and saliva, enabled rapid pivoting to detect new virus variants, and facilitated highly sensitive, point-of-care diagnosis of COVID-19 in clinical and public health settings.

KW - COVID-19

KW - diagnostic

KW - point-of-care

KW - Raman spectroscopy

KW - SARS-CoV-2

KW - scFv antibody fragment

KW - SERS

UR - http://www.scopus.com/inward/record.url?scp=85126604039&partnerID=8YFLogxK

U2 - 10.1021/acssensors.1c02664

DO - 10.1021/acssensors.1c02664

M3 - Article

C2 - 35271769

AN - SCOPUS:85126604039

SN - 2379-3694

VL - 7

SP - 866

EP - 873

JO - ACS Sensors

JF - ACS Sensors

IS - 3

ER -

Rapid, Point-of-Care scFv-SERS Assay for Femtogram Level Detection of SARS-CoV-2

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this